ArticlePharmacological reports : PR2026
Naringenin and quercetin alter mouse rod phototransduction kinetics in a manner consistent with phosphodiesterase-6 inhibition.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe flavonoids naringenin and quercetin are promising therapeutic agents for a wide variety of diseases, including inherited retinal degenerations (IRDs), thanks to their antioxidant, anti-inflammatory, and other properties. Among these are their inhibition of some phosphodiesterase (PDE) isoforms. However, it is unknown how they affect the photoreceptor-specific PDE6, which is critical for phototransduction. This interaction is key for understanding their therapeutic potential in IRDs and the risk of visual side effects more broadly. We aimed to determine if they inhibit PDE6 in living mouse retinae at pharmacologically relevant concentrations.
methodsWe used ex vivo electroretinography to record pharmacologically isolated rod a-waves from mouse retinae at 37 °C. One retina received naringenin or quercetin, while the other received the vehicle. We analysed flash response parameters: light sensitivity, time-to-peak, amplification constant (derived by fitting responses with a biophysical model), and saturating amplitude.
resultsBoth flavonoids rapidly decreased amplification, in line with inhibition of light-activated PDE6 with a [Formula: see text] of 7.1 µM for naringenin and 15.1 µM for quercetin. Naringenin increased saturating amplitude, consistent with inhibiting dark-state PDE6. Quercetin induced a secondary slowing of phototransduction cascade termination kinetics independent of its effect on amplification, suggesting inhibition of a cascade shutdown protein.
conclusionsThese findings are key to evaluating the visual safety of high-dose flavonoid therapies. They also raise the possibility that direct effects on phototransduction could play a role in their neuroprotection in IRDs.
Indexed as
Identifiers
41656402What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.